{
  "url": "https://allermi-site.vercel.app/compare/astepro-vs-dymista/",
  "collection": "compare",
  "slug": "astepro-vs-dymista",
  "frontmatter": {
    "title": "Astepro vs Dymista: OTC Antihistamine vs Rx Combo",
    "description": "Standalone azelastine OTC vs Rx azelastine-plus-fluticasone combo: when does adding the steroid matter?",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "astepro vs dymista",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Astepro is OTC azelastine alone. Dymista is Rx azelastine + fluticasone in one bottle. For mild-moderate sneezing/itching, Astepro is enough. For moderate-severe AR with congestion, Dymista outperforms either component alone per Carr 2012 RCT. Cost differs: Astepro ~$16–25/mo OTC; Dymista cash $54–260/mo (often much lower insured).",
    "claims": [
      "c-035",
      "c-036",
      "c-039",
      "c-040",
      "c-048",
      "c-078"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Astepro = OTC azelastine alone (fast onset, no steroid)",
        "tier": "fda-label"
      },
      {
        "text": "Dymista = Rx azelastine + fluticasone combo",
        "tier": "fda-label"
      },
      {
        "text": "Dymista outperforms either component alone",
        "tier": "rct",
        "detail": "Carr 2012"
      }
    ],
    "related": [
      {
        "href": "/reviews/astepro/",
        "label": "Astepro review",
        "kind": "Product",
        "description": "OTC azelastine: onset, side effects, pediatric notes."
      },
      {
        "href": "/reviews/dymista/",
        "label": "Dymista review",
        "kind": "Product",
        "description": "Rx fixed-dose azelastine + fluticasone combo."
      },
      {
        "href": "/reviews/flonase/",
        "label": "Flonase review",
        "kind": "Product",
        "description": "The steroid component: available OTC alone."
      },
      {
        "href": "/compare/flonase-vs-astepro/",
        "label": "Flonase vs Astepro",
        "kind": "Head-to-head",
        "description": "OTC stack rationale: the components of Dymista."
      },
      {
        "href": "/compare/flonase-vs-dymista/",
        "label": "Flonase vs Dymista",
        "kind": "Head-to-head",
        "description": "Steroid alone vs Rx combo: mirror comparison."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Where adding a steroid to Astepro makes the biggest difference."
      },
      {
        "href": "/symptom/itchy-nose/",
        "label": "Best nasal spray for itchy nose",
        "kind": "Symptom",
        "description": "Azelastine's 15-min histamine block stays central."
      }
    ],
    "subjects": [
      {
        "id": "astepro",
        "name": "Astepro"
      },
      {
        "id": "dymista",
        "name": "Dymista"
      }
    ]
  },
  "outline": [
    {
      "id": "which-should-you-pick",
      "text": "Which should you pick?",
      "children": []
    },
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 3,
    "guideline": 0,
    "fdaLabel": 2,
    "cohort": 0,
    "expert": 1
  },
  "claimIds": [
    "c-035",
    "c-036",
    "c-039",
    "c-040",
    "c-048",
    "c-078"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi (outperforms both Astepro and Dymista)\"\n body=\"Astepro is OTC azelastine alone. Dymista adds fluticasone. For eligible patients 13+, our overall pick is Allermi: it adds ipratropium (anticholinergic, for drip) and micro-dosed oxymetazoline (for congestion) on top of the steroid plus antihistamine pair in Dymista, in one personalized bottle reviewed by a prescribing allergist.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy, breastfeeding, or under-13 (or under-18 in AK/NM/OR/SC). Astepro remains OTC and Dymista stays available by Rx; check allermi.com/pages/qualifier-quiz.\"\n/>\n\n<Claim id=\"c-035\">In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray</Claim> <Claim id=\"c-036\">In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)</Claim> <Claim id=\"c-039\">Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older</Claim> <Claim id=\"c-040\">In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis</Claim> <Claim id=\"c-048\">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id=\"c-078\">Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon</Claim>\n\n## Which should you pick?\n\nFor [mild-moderate itchy nose](/symptom/itchy-nose/) and sneezing without much congestion, standalone [Astepro](/reviews/astepro/) is sufficient and OTC. For moderate-severe AR (particularly with [nasal congestion](/symptom/congestion/) as a dominant symptom), adding the fluticasone component matters; [Dymista](/reviews/dymista/) provides both actives in one bottle via Rx. If an Rx is inconvenient, the OTC stack of Astepro + [Flonase](/reviews/flonase/) is pharmacologically equivalent (see the [Flonase vs Astepro](/compare/flonase-vs-astepro/) discussion for the stacking rationale).\n\nThe mirror comparison (Flonase, the steroid alone, versus Dymista, the combo) is covered on the [Flonase vs Dymista](/compare/flonase-vs-dymista/) page.\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nIf you are weighing Astepro against Dymista, you are already in combination-therapy territory. For eligible patients 13+, [Allermi](/reviews/allermi/) is our overall pick: the same steroid + antihistamine pair Dymista proves in RCT, plus ipratropium and micro-dosed oxymetazoline, personalized to your intake.\n\n<AllermiPickCallout\n title=\"Not sold on either Astepro or Dymista? Allermi outperforms both for eligible adults.\"\n body=\"Four actives, allergist-reviewed, one bottle. Patients 13+ only.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"Carr 2012: Dymista RCT\", url: \"https://pubmed.ncbi.nlm.nih.gov/22418065/\", publisher: \"PubMed\", year: 2012 }\n]} />",
  "claims": [
    {
      "id": "c-035",
      "claim": "In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213872Orig1s000Lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "astepro"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-036",
      "claim": "In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/19930788/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "astepro",
        "dymista",
        "allermi"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-039",
      "claim": "Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c557ec4-c4cf-11df-851a-0800200c9a66",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-040",
      "claim": "In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-048",
      "claim": "Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista",
        "flonase",
        "astepro",
        "allermi"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-078",
      "claim": "Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon",
      "source_type": "GoodRx",
      "confidence": "medium",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.goodrx.com/dymista"
    }
  ]
}